Real-World Considerations for New Therapies

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

New therapies must show significant clinical improvements, such as enhanced efficacy or reduced side effects, over current standards to be considered for adoption.
Cost-effectiveness, ease of administration, and alignment with existing protocols are crucial non-clinical factors influencing treatment adoption decisions.
The impact on healthcare resources, infrastructure, and acceptance by patients and providers are critical considerations in evaluating new therapies.

Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

Now Viewing

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

EP: 17.Final Thoughts

Video content above is prompted by the following:

What clinical improvements would a new therapy need to demonstrate over the current standard of care to warrant consideration for adoption, and what additional factors influence your decision-making process when evaluating treatment changes?